Physician profile
Ashley Matney
NPI 1558654806
$2,604.53
in general payments reported to CMS, 2019-2025
25 companies · $77.50 in 2025
The $77.50 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $664 · 2020: $537 · 2021: $722 · 2022: $272 · 2023: $299 · 2024: $34.52 · 2025: $77.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $411.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $410.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $328.64 | 2019-2025 | |
| Amgen INC. | $264.43 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $247.24 | 2019-2024 | Jardiance |
| Lilly USA, LLC | $215.01 | 2019-2021 | |
| Novo Nordisk INC | $184.97 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $172.18 | 2019-2022 | |
| Amarin Pharma, INC. | $157.32 | 2019-2021 | |
| Dexcom, INC. | $151.67 | 2021-2023 | Dexcom G7 Gss (161) |
| Merz North America, INC. | $150.00 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $139.32 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $99.84 | 2019-2022 | |
| Abbvie INC. | $93.11 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.69 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $87.64 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $66.19 | 2020-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $33.18 | 2021 | |
| Sanofi Pasteur INC. | $18.14 | 2019 | |
| Mylan Specialty L.P. | $17.63 | 2024 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.26 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.63 | 2022 | |
| Mannkind Corporation | $12.34 | 2021 | |
| Novartis Pharmaceuticals Corporation | $11.92 | 2022 | |
| Eisai INC. | $11.87 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.67 | 2019 | |
| Esperion Therapeutics, INC. | $11.64 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Matney listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.